http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-199900467-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
filingDate 1999-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88ddfc866bfa93f8bfcd75a890758fdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_995a8b5434164c1ab382da2d9ba2c631
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51885983ff9607648aa506d3bb6ef59c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be8d8e23e9c4657220293caab3363ca5
publicationDate 1999-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EA-199900467-A2
titleOfInvention COMPOSITIONS BASED ON ZIPRAZIDONA
abstract Compositions comprising crystalline ziprasidone free base particles or crystalline ziprasidone hydrochloride particles having an average particle size of less than 85 microns and a pharmaceutically acceptable carrier are substantially bioequivalent and can be used to treat psychosis such as schizophrenia.
priorityDate 1998-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507324
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60854

Total number of triples: 34.